Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $56

Futu NewsJan 8 19:31 · Ratings

Kymera Therapeutics: Promising Prospects With Targeted Protein Degradation and Innovative Drug KT-621

TipRanksJan 8 19:26

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

GlobeNewswireJan 7 20:00

Brookline Capital Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $97

Futu NewsJan 7 00:32 · Ratings

Jefferies Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $59

Futu NewsJan 2 23:32 · Ratings

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Kymera Therapeutics (KYMR) and Sarepta Therapeutics (SRPT)

TipRanksJan 2 23:20 · Ratings